Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs)
The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.